Skip to main content
. 2023 Feb 18;182(4):1897–1909. doi: 10.1007/s00431-023-04862-z

Table 3.

Bivariable analysis of the treatment of MIS-C cases according to SARS-CoV-2 variant periods

Characteristics All MIS-C Wuhan period Alpha period Delta period Omicron period p-val
Immunomodulatorya 146 67 5 44 30 0.39
Only IGIV (n = 8) 8 (5.5) 6 (9.0) 0 (0.0) 1 (2.3) 1 (3.3) 0.76
Only steroids (n = 18) 18 (12.3) 7 (10.4) 1 (20.0) 7 (15.9) 3 (10.0) 0.86
IGIV and steroids (n = 120) 120 (82.2) 54 (80.6) 4 (80.0) 36 (81.8) 26 (86.7) 0.71
  First IGIV (n = 13)b 13 (10.8) 7 (13.0) 1 (25.0) 2 (5.6) 3 (11.5) 0.96
  IGIV and steroids at once (n = 88)b 88 (73.3) 37 (68.5) 3 (75.0) 27 (75.0) 21 (80.8) 0.67
  First steroids (n = 11)b 11 (9.2) 6 (11.1) 0 (0.0) 3 (8.3) 2 (7.7) 1
  Unknown order (n = 8)b 8 (6.7) 4 (7.4) 0 (0.0) 4 (11.1) 0 (0.0) 0.7
Steroids (days of treatment), median [IQR] 11 [4–22] 19 [4–25] 4 [3.5–16.5] 6.5 [4–17] 9 [5–13] 1
Anakinra (n = 1) 1 (0.7) 1 (0.7) 0 0 0 1
Adjuvant treatmentc (MIS-C cases) 152 73 5 44 30 1
  Oxygen treatment 7 (4.6) 5 (6.8) 0 2 (4.6) 0 0.83
  ECMO 1 (0.7) 1 (1.4) 0 0 0 1
  IMV 3 (2.0) 2 (2.7) 0 1 (2.3) 0 1
  NIV 3 (2.0) 2 (2.7) 0 1 (2.3) 0 1
  Hemofiltration 2 (1.3) 1 (1.4) 0 0 1 (3.3) 0.83
  Inotropic 48 (31.6) 24 (32.9) 0 14 (31.8) 10 (33.3) 1
  Antibiotics 124 (81.6) 59 (80.8) 5 (100) 36 (81.8) 24 (80.0) 1
  Other treatmentsd 40 24 0 13 3 0.47

aTotal number of cases (n) refers to all the cases for which steroids, IGIV, or both of them were administered

bPercentages for subcategories refer to the number of cases receiving IGIV and/or steroids

cTotal number of cases (n) refers to all MIS-C cases included in the study

dOther treatments include: AAS (n = 29), enoxaparin (n = 11), hydroxychloroquine (n = 2), remdesivir (n = 1), insulin (n = 1), vitamin K (n = 1)